Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure

NCT06935409 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

117

Enrollment

INDUSTRY

Sponsor class

Conditions

Osteosarcoma

Interventions

DRUG: HS-20093
DRUG: Gemcitabine combined with docetaxel

Sponsor

Hansoh BioMedical R&D Company